Home | Links | Contact Us | More About Intellectual Property | Bookmark
Search patents:
Home Gene Therapy Method-for-treating-sickle-cell-disease

 Sugar modified nucleosides and oligonucleotides
What is claimed is: 1. A nucleoside having the structure: ##STR6## wherein: R.sub.2 is selected ...


 Methods and compositions for administration of iron for the treatment of restless leg syndrome
1. A method of treating Restless Leg Syndrome, comprising administering to a subject an iron ...


 C-reactive protein fragment with immunomodulatory activity
OF THE INVENTION Abbreviations and Definitions The abbreviations for the various common amino ...


 Pharmaceutical compositions for promoting the growth of gram-positive bacilli and increasing the acidity in the vagina and the use thereof
OF THE INVENTION As mentioned above, this invention relates to water-based pharmaceutical ...


 Method of preparing a lipoprotein modified by incorporation of a lipophilic active substance
OF THE PREFERRED EMBODIMENTS The method according to the invention may also have the ...


 Microemulsions used as vehicles for carrying chemotherapeutic agents to neoplastic cells
What is claimed is: 1. A method for treating neoplasms, wherein cells from said neoplasms have an ...


 Oral pharmaceutical composition for soft capsules containing vinorelbine and method of treatment
OF THE INVENTION The term "pharmaceutically acceptable salt" within the context of vinorelbine is ...


 Connective tissue growth factor (CTGF) regulatory nucleic acid sequences
Various cell types produce and secrete PDGF and PDGF-related molecules. In an attempt to identify ...


 Process for producing humanized chimera antibody
The present invention relates to a process for producing humanized chimera antibody which comprises ...


 Methylation analysis using nicking agents
OF THE INVENTION The present invention provides simple and efficient methods for characterizing ...


 Method for treating sickle cell disease

Details
Inventors: Hunter, Robert L.; Duncan, Alexander;
Assignee: Emory University (Atlanta, GA)
Primary Examiner: Rollins; John W.
Assistant Examiner:
Attorney, Agent or Firm: Jones, Askew & Lunsford

In accordance with the present invention, a method is provided for treating sickle cell anemia. The method comprises injecting an effective concentration of a surface active copolymer into the patient with sickle cell anemia. The surface active copolymer can be an ethylene oxide-propylene oxide condensation product with the following general formula: HO(C.sub.2 H.sub.4 O).sub.b (C.sub.3 H.sub.6 O).sub.a (C.sub.2 H.sub.4 O).sub.b H wherein a is an integer such that the hydrophobe represented by (C.sub.3 H.sub.6 O) has a molecular weight of approximately 950 to 4000, preferably approximately 1200 to 3500, and b is an integer such that the hydrophile portion represented by (C.sub.2 H.sub.4 O) constitutes approximately 50% to 90% by weight of the compound.

DETAILED DESCRIPTION OF THE DISCLOSED EMBODIMENT The present invention comprises a composition which provides a synergistic action in lysing blood clots and reestablishing and maintaining blood flow through a thrombosed coronary vessel or other blood vessel.
The fibrinolytic composition of the present invention is a solution containing an effective concentration of a fibrinolytic enzyme and an effective concentration of a surface-active copolymer.
The combination of the two components is effective in dissolving blood clots that are blocking blood vessels.
In addition, the fibrinolytic composition of the present invention is highly effective in preventing a blood clot from reforming and in maintaining blood flow through the blood vessel and affected ischemic tissue.
The fibrinolytic composition of the present invention improves the flow of blood through narrow channels around clots and increases the delivery of the fibrinolytic enzyme to the clot.
The present invention also speeds the rate of dissolution of the clot by the enzyme and increases the proportion of clots lysed by promoting delivery of enzyme to clots which would not otherwise be exposed to sufficient enzyme for their dissolution.
In addition, the fibrinolytic composition of the present invention reduces the dose of enzyme required for particular applications and thereby reduces the incidence of complications due to side effects caused by the enzymes.
The fibrinolytic composition of the present invention reduces the risk of immediate rethrombosis by accelerating the dissolution of clots, freeing aggregated platelets and blocking further platelets from aggregating to the clot or clot site.
By reducing the risk of immediate rethrombosis, the fibrinolytic composition of the present invention will allow delay of balloon angioplasty or other invasive procedures for treatment of the compromised vessels which have become thrombosed.
The delay will permit selection of conditions for invasive treatment most favorable to the patient.
Solutions which may be employed in the preparation of the fibrinolytic composition of the present invention include, but are not limited to, saline (a solution of sodium chloride, containing 8


Related patents
  Method and composition for reducing tissue damage
OF THE DISCLOSED EMBODIMENT The present invention comprises a composition which provides a synergistic action in lysing blood clots and reestablishing and maintaining ...
  Tissue plasminogen activator having zymogenic or fibrin specific properties and substituted at amino acid positions 296-299, DNA molecules encoding them, vectors, and host cells
These objects are achieved by the provision of a tissue plasminogen activator (t-PA) zymogen capable of converting to the enzymatically active form of t-PA upon cleavage ...
  Dramatic simplification of a method to treat neoplastic disease by radiation
OF THE INVENTION I. Simplification of a Complex Protocol CldC and a single coadministered cytidine deaminase inhibitor, such as Tetrahydrouridine (H4U) or Zebularine (Z...
  Compounds
1. A compound of formula (II): ##STR14## where R1 is C3-5 alkyl optionally substituted by 1 or more halogen atoms; R3 and R4 are both hydroxy; R is XOH, where X is OCH2CH...
  Calcium hypochlorite blended tablets
OF THE INVENTION The term "non-Division 5.1 Oxidizer composition" as used in the present specification and claims refers to any blend of calcium hypochlorite hydrate ...
  Isolation of exogenous recombinant proteins from the milk of transgenic mammals
OF THE INVENTION This invention relates to processes, DNA sequences, compositions of matter and transgenic mammals for the production of recombinant proteins More ...
  Methods for predicting the behaviour of breast tumours
What is claimed is: 1. A method of determining the risk of metastasis of a female breast tumour, which comprises determining whether a tissue sample from said tumour ...
  Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
In a first embodiment, there is provided a method, for evaluating a biological condition of a subject, based on a sample from the subject. The method includes: deriving ...
  Functional DNA clone for hepatitis C virus (HCV) and uses thereof
The present invention advantageously provides an authentic hepatitis C virus (HCV) DNA clone capable of replication, expression of functional HCV proteins, and infection ...
  Self-replicating RNA molecule from hepatitis C virus
OF THE DRAWINGS FIG. 1 is a schematic view of the bi-cistronic replicon RNA. The sequence deviations between the 1377/NS2-3' replicon from Lohman et al., 1999 Science 28...

0.014

Archive: All patents - Links

Copyright (c)2006 Eipa-patents.org - All rights reserved